Loading clinical trials...
Loading clinical trials...
A Phase 1/2, Multicenter, Open-label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)
Conditions
Interventions
BMN 110
Locations
3
United Kingdom
Birmingham, United Kingdom
London, United Kingdom
Manchester, United Kingdom
Start Date
April 1, 2009
Primary Completion Date
February 1, 2011
Completion Date
March 1, 2011
Last Updated
June 30, 2014
NCT03632213
NCT01242111
NCT00787995
Lead Sponsor
BioMarin Pharmaceutical
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions